Source comparison
CJC-1295 vs Sermorelin GH Peptide Wins: Performance Comparison Across Research Contexts
Half-Life 6–8 days 8–12 minutes 30 minutes CJC-1295 with DAC leads for sustained exposure models; sermorelin for acute pulse studies Dosing Frequency Once weekly Daily Daily to twice daily CJC-1295 reduces protocol complexity in long-term studies; sermorelin r
This comparison does not assign a generated winner or score.
- Half-Life
- 6–8 days
- 8–12 minutes
- 30 minutes
- CJC-1295 with DAC leads for sustained exposure models; sermorelin for acute pulse studies
- Dosing Frequency
- Once weekly
- Daily
- Daily to twice daily
- CJC-1295 reduces protocol complexity in long-term studies; sermorelin requires stricter compliance
- IGF-1 Elevation Speed
- Peak at 3–4 days
- Gradual over 2–4 weeks
- Moderate over 1–2 weeks
- CJC-1295 produces faster measurable downstream effects for time-sensitive endpoints
- Pulsatility Preservation
- None. Continuous elevation
- Fully preserved
- Partially preserved
- Sermorelin is mandatory for studies examining natural secretory dynamics or circadian patterns
- Receptor Desensitisation Risk
- High after 8–12 weeks
- Minimal
- Low to moderate
- Sermorelin maintains responsiveness across extended timelines; CJC-1295 requires cycling or lower doses
- Cost Per Dose
- Higher per injection but fewer doses
- Lower per dose but daily requirement
- Moderate
- Total protocol cost favours CJC-1295 for <12-week studies; sermorelin for >16 weeks
- Optimal Research Context
- Chronic metabolic exposure, stable baseline studies
- Acute signaling cascades, receptor sensitivity studies, pediatric growth models
- Hybrid protocols requiring moderate duration with daily flexibility
- Context-dependent. No universal winner